Samsung Biologics has secured a massive contract manufacturing organization (CMO) deal worth 1.8 trillion KRW (approximately $1.30 billion USD) with a U.S. pharmaceutical company.
This accomplishment comes amid global economic uncertainties, including tariff risks and reshoring pressure originating from the U.S. Trump administration.
In a public disclosure on Tuesday, Samsung Biologics announced that it had signed a pharmaceutical manufacturing agreement with a U.S.-based firm.
The contract, valued at 1.8006 trillion KRW (approximately $1.30 billion), covers the period from August 29, 2025, to December 31, 2029. This amount is equivalent to 39.6% of the company’s consolidated revenue from the previous year, which amounted to approximately 4.5473 trillion KRW (approximately 3.23 billion USD).
The significance of the deal is heightened by its timing, as it coincides with a challenging export landscape to the U.S. due to increased tariffs and aggressive reshoring policies.
Industry analysts credit Samsung Biologics’ competitive advantage to its world-leading production capacity of 784,000 liters and an outstanding record of 382 global regulatory approvals.
This recent contract is expected to accelerate Samsung Biologics’ expansion of its partnerships with major global pharmaceutical companies.
A spokesperson for Samsung Biologics stated, “We will accelerate our global growth strategy by leveraging our robust quality assurance and industry credibility.”
Meanwhile, the identity of the U.S. pharmaceutical partner was not disclosed due to confidentiality reasons. The contract’s end date may be subject to future negotiations.
